ES2747303T3 - Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico - Google Patents

Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Download PDF

Info

Publication number
ES2747303T3
ES2747303T3 ES16177827T ES16177827T ES2747303T3 ES 2747303 T3 ES2747303 T3 ES 2747303T3 ES 16177827 T ES16177827 T ES 16177827T ES 16177827 T ES16177827 T ES 16177827T ES 2747303 T3 ES2747303 T3 ES 2747303T3
Authority
ES
Spain
Prior art keywords
crystals
hydrochloride salt
fluoroethyl
oxo
dihydroquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16177827T
Other languages
English (en)
Spanish (es)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2747303(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2747303T3 publication Critical patent/ES2747303T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES16177827T 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Active ES2747303T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27

Publications (1)

Publication Number Publication Date
ES2747303T3 true ES2747303T3 (es) 2020-03-10

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP2778159B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR102162208B1 (enExample)
CN (2) CN103930414B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2747303T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2615509C2 (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG11201401817TA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP5651812B1 (ja) * 2013-04-25 2015-01-14 杏林製薬株式会社 固形医薬組成物
JP5700740B1 (ja) * 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6018334B2 (ja) * 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
JP6077725B1 (ja) * 2015-03-13 2017-02-08 杏林製薬株式会社 呼吸器感染症治療剤
CA2988092A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
US10206917B2 (en) * 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
MX2019014931A (es) 2017-06-16 2020-02-13 Kyorin Seiyaku Kk Agente terapeutico para neumonia por aspiracion, supuracion pulmonar, o absceso pulmonar.
CN116549446A (zh) * 2017-06-16 2023-08-08 杏林制药株式会社 吸入性肺炎、肺化脓或肺脓肿的治疗剂
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030124028A1 (en) * 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
JPWO2003076428A1 (ja) * 2002-03-08 2005-07-07 第一製薬株式会社 キノロンカルボン酸誘導体
DK1666477T3 (da) 2003-09-10 2013-07-29 Kyorin Seiyaku Kk 7-(4-trisubstitueret 3-cyclopropylaminomethyl-1- pyrrolidinyl)-quinoloncarboxylsyre-derivat
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
CA2855022C (en) 2019-05-07
NZ623808A (en) 2015-07-31
RU2615509C2 (ru) 2017-04-05
JP2018158949A (ja) 2018-10-11
CA2855022A1 (en) 2013-05-16
JP5871948B2 (ja) 2016-03-01
AU2016273899B2 (en) 2017-07-27
US9328089B2 (en) 2016-05-03
JP6349435B2 (ja) 2018-06-27
AU2012337206A8 (en) 2016-09-22
AU2016273899A1 (en) 2017-01-12
RU2017109814A (ru) 2019-01-23
KR20190065456A (ko) 2019-06-11
RU2014123567A (ru) 2015-12-20
BR112014010765B1 (pt) 2020-07-14
TWI547492B (zh) 2016-09-01
EP3112359B1 (en) 2019-08-21
EP2778159B1 (en) 2017-03-01
US20150284361A1 (en) 2015-10-08
ES2621664T3 (es) 2017-07-04
USRE47785E1 (en) 2019-12-31
CN103930414B (zh) 2016-01-20
AU2012337206A1 (en) 2014-05-22
CN104945375B (zh) 2017-07-04
CN103930414A (zh) 2014-07-16
EP2778159A1 (en) 2014-09-17
AU2012337206B2 (en) 2016-09-15
TW201332991A (zh) 2013-08-16
US9090587B2 (en) 2015-07-28
EP3112359A1 (en) 2017-01-04
BR112014010765A2 (pt) 2017-06-13
JP6514069B2 (ja) 2019-05-15
CN104945375A (zh) 2015-09-30
JP2017160243A (ja) 2017-09-14
WO2013069297A1 (ja) 2013-05-16
SG10201608167UA (en) 2016-11-29
EP2778159A4 (en) 2015-06-03
SG11201401817TA (en) 2014-08-28
SA112330992B1 (ar) 2015-09-13
KR102162208B1 (ko) 2020-10-06
KR20140098074A (ko) 2014-08-07
JP6818719B2 (ja) 2021-01-20
JPWO2013069297A1 (ja) 2015-04-02
IN2014DN03277A (enExample) 2015-05-22
US20140288310A1 (en) 2014-09-25
JP2016027045A (ja) 2016-02-18
RU2017109814A3 (enExample) 2020-04-08
MX375073B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
ES2747303T3 (es) Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
ES2909198T3 (es) Proceso para la preparación de pleuromutilinas
CN114728899A (zh) 新型三苯基化合物盐
ES2828636T3 (es) Sal agonista de receptores opioides (MOR), forma cristalina I de la sal de fumarato de la misma y método de preparación de las mismas
CN117645627A (zh) 杂环类化合物及其医药用途
ES2699884T3 (es) Nuevo compuesto cristalino de arilalquilamina y método para producir el mismo
US10406149B2 (en) Aqueous liquid formulation
AU2012337206B8 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
MX2014005007A (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
HK40076742B (zh) 新型三苯基化合物盐